Effects of Zinc Supplementation on the Anthropometric Measurements, Lipid Profiles and Fasting Blood Glucose in the Healthy Obese Adults by Sepide Mahluji et al.
 
 
Advanced Pharmaceutical Bulletin, 2013, 3(1), 161-165 
doi: http://dx.doi.org/10.5681/apb.2013.027 
http://apb.tbzmed.ac.ir/ 
 
*Corresponding author: Alireza Ostadrahimi, Nutrition Research Center, Faculty of Health and Nutrition, Tabriz University of Medical Science, 
Tabriz, Iran. Email: ostadrahimi@tbzmed.ac.ir 
Copyright © 2013 by Tabriz University of Medical Sciences 
Effects  of  Zinc  Supplementation  on  the  Anthropometric 
Measurements,  Lipid  Profiles  and  Fasting  Blood  Glucose  in  the 
Healthy Obese Adults 
Laleh Payahoo
1, Alireza Ostadrahimi
1*, Majid Mobasseri
2, Yaser Khaje Bishak
1, Nazila Farrin
1, Mohammad 
Asghari Jafarabadi
3, Sepide Mahluji
1 
1 Nutrition Research Center, Faculty of Health and Nutrition, Tabriz University of Medical Science, Tabriz, Iran.  
2 Department of Internal Medicine, Tabriz University of Medical Science, Tabriz, Iran.  
3 Tabriz Health Management Research Center, Faculty of Health and Nutrition, Tabriz University of Medical Science, Tabriz, Iran.
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Obesity  has  become  one  of  the  major  public-health 
concerns  in  the  world
1  which  is  correlated  with  the 
incidence of many chronic diseases such as metabolic 
syndrome  (MS),  diabetes,  cardiovascular  diseases, 
certain cancers, respiratory disease, etc.
2-4 According to 
the World Health Organization (WHO) report, there are 
over 400 million obese and over 1.6 billion overweight 
adults in the world and it is estimated to be double by 
2015. This concern is not restricted just to adults; at 
least  20  million  children  under  the  age  of  5  were 
recognized as overweight in 2005.
5 The prevalence of 
obesity  in  Iran  has  been  estimated  to  be  10.5%  and 
22.5% in men and women, respectively which indicates 
an obvious increase during a 14-year period.
6 
Obese people have high amounts of fat mass especially 
in  adipose  tissues.  Plasma  fatty  acids  are  constantly 
influenced  by  adipose  tissue  fatty  acids.
7  Plasma 
triacylglycerols  are  the  major  source  of  endogenous 
and exogenous fatty acids for the synthesis of complex 
lipids. The type of fatty acids in adipose tissue might 
exert  a  direct  influence  on  serum  lipids  and  the 
abnormality of serum lipids can affect the incidence of 
atherosclerosis,  MS,  and  other  chronic  diseases. 
Therefore, adipose tissue region has an important role 
in the development of diseases. It has been suggested 
that intra-abdominal fat has a higher turnover rate than 
subcutaneous fat.
8 and it may have a greater influence 
on the plasma lipid profiles. Abdominal fat has been 
associated with insulin resistance, hyperlipidemia and 
hypertension, certain types of cancer and osteoporosis.
9  
Recently, nutritional, hormonal, and biochemical status 
of obese patients are being attended by reserchers.
9-12 
Overweight  and  obese  individuals  have  lower  blood 
level  of  vitamins  and  minerals  compared  to  non-
overweight  and  non-obese  individuals.
13  zinc 
concentration  in  plasma,  serum  and  erythrocytes  of 
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Purpose: The aim of this study was to assess the effects of zinc supplementation on 
anthropometric measures, improving lipid profile biomarkers, and fasting blood glucose 
level  in  obese  people.  Methods:  This  randomized,  double-  blind  clinical  trial  was 
carried  out  on  60  obese  participants  in  the  18-45  age  range  for  one  month.  The 
participants were randomly divided into the intervention group, who received 30 mg/d 
zinc gluconate,  and the  placebo group  who received  30mg/d starch.  Anthropometric 
measurements (body mass index (BMI), weight and waist circumference) were recorded 
before and at the end of study. Lipid profile biomarkers and fasting blood glucose were 
determined using enzymatic procedure. Analysis of Covariance (ANCOVA) test was 
run to compare the post-treatment values of the two groups, and t-test was conducted to 
compare  within  group  changes.  Results:  Serum  zinc  concentration  was  increased 
significantly in intervention group (p=0.024). BMI and body weight was significantly 
decreased  (p=0.030  and  p=0.020,  respectively).  Lipid  profile  biomarkers  and  fating 
blood  glucose  did  not  change  significantly  but  triglyceride  level  was  significantly 
decreased  (p=0.006)  in  the  intervention  group.  Conclusion:  The  obtained  results 
indicate  that  zinc  supplementation  improves  BMI,  body  weight,  and  triglyceride 
concentration without considerable effects on lipid profile and glucose level. Zinc can 
be suggested as a suitable supplementation therapy for obese people, but more studies 
are needed to verify the results.  
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obese people is considered to be low.
14-15 Zinc, as an 
important  micronutrient,  plays  a  key  role  in 
macronutrient metabolism
16 as well as appetite control. 
In  addition,  zinc  is  involved  in  synthesis,  storage, 
release, and action of insulin.
17,18 and its deficiency is 
associated  with  insulin  resistance,  impaired  glucose 
tolerance and obesity.
19,20  
Weight  loss  is  an  effective  approach  in  controlling 
obesity and it has been demonstrated that weight loss 
improves plasma concentration of glucose, insulin and 
lipids. Moreover, weight loss has a positive effect on 
increasing plasma zinc concentration.
21-23 The present 
study  set  out  to  investigate  the  effects  of  zinc 
supplementation  on  anthropometric  measurements, 
lipid profiles and fasting blood glucose in healthy obese 
people. 
 
Materials and Methods 
This  randomized,  double-  blind,  placebo-controlled 
clinical  trial  was  performed  on  60  healthy  obese 
participants.  The  research  protocol  was  approved  by 
regional  Ethic  Committee  of  Tabriz  University  in 
Medical Sciences. Clinical Trial Number was Irct ID: 
IRCT201112222017N5 with URL: www.irct.IR 
Inclusion  criteria  were  the  age  range  of  18-45, 
nonsmoking, body mass index (BMI) between 30 and 
40  (Kg/m
2),  while  exclusion  criteria  included 
pregnancy,  breastfeeding  and  postmenopausal  among 
women,  as  well  as  current  clinical  diseases  specially 
gastrointestinal, liver and kidney, diabetes, and thyroid. 
Excluded from the study were also individuals who had 
defective immune systems, were using drugs that could 
interact with serum lipid profiles and weight loss, were 
consuming  anti-coagulant  drugs  and  beta  blockers 
users, were  taking  mineral supplements  such  as  zinc, 
Iron, calcium and vitamin A during the past 3 months, 
and finally those who were on a diet restriction. After 
explaning the nature of the study, a written informed 
consent was taken from the participants. 
The  eligible  participants  were  randomly  allocated  to 
intervention-placebo  groups  based  on  random  block 
procedure  produced  by  Random  Allocation  Software 
(RAS).
24  Sample  size  was  determined  based  on  the 
information  derived  from  the  same  study.
25  The 
confidence level was set at 95% and the formula N= 
[(Z1-α/2  +  Z1-B)
2  (SD1
2+SD2
2)]  /Δ
2  was  used  to 
calculate the 30 samples in each group. For one month, 
the  Zinc  group  (n=30)  had  received  a  30mg  zinc 
gluconate  tablet  per  day  while  the  placebo  group 
(n=30) had received 30mg placebo (starch) tablet per 
day. Tablets of the same color and shape were placed 
by a third person who labeled the bottles with 2 cods 
which remained unknown for the researchers until the 
end of the intervention. All the participants were asked 
not  to  change  their  usual  dietary  intakes  during  the 
study.  To  ensure  that  the  participants  would  act  in 
compliance  with  the  prescriptions,  they  were  weekly 
reached on phone and were required to return the tablet 
bottles at the end of the study so that the remainder of 
the  tablets  could  be  checked.  Subsequent  statistical 
analysis  was  carried  out  based  on  the  data  obtained 
from  the  participants  who  had  consumed  more  than 
90% of the tablets. 
Blood samples were taken in a 12 hour fasting state at 
the beginning  and  the  end  of  study  and  were  further 
frozen in -70 ºC for biochemical analysis.  
Demographic  information  was  collected  through 
questionnaires.  Body  weight  was  measured  without 
shoes  and  light  clothes  by  using  a  Seca  scale  (Seca, 
Hamburg, Germany). Height was also measured using 
a statiometer (Seca) without shoes. BMI was calculated 
as  weight  (in  kilograms)  divided  by  the  square  of 
height  (in  meters).  Waist  circumference  (WC)  was 
measured with a statiometer (Seca).  
Serum  zinc  concentration  was  estimated  by  atomic 
absorption spectrometry (Chem Tech Analytical, CTA 
2000, English).
26 Serum concentrations of triglyceride 
(TG),  total  cholesterol  (TC),  high-density  lipoprotein 
cholesterol (HDL-C), and fasting blood glucose (FBS) 
were  determined  using  kit  (Parsazmon,  Tehran,  Iran) 
and  enzymatic  method.  Low-density  lipoprotein 
cholesterol  (LDL-C)  was  calculated  according  to  the 
procedure of Friede-Wald formula. 
 
Statistical Analysis 
The  data  were  analyzed  by  SPSS  software  (version 
16:0, Shikagho.IL, USA). Quantitative data were stated 
as mean ± standard deviation (SD) and qualitative data 
were presented as frequency (percentage). Normality of 
variables  distribution  was  evaluated  using 
Kolmogorov-Smirnov  test.  Paired  t-test  was  used  to 
compare  within  group  changes  before  and  after  the 
intervention. Analysis of Covariance (ANCOVA)  test 
was also run to compare post treatment variables after 
adjusting  for  baseline  values  in  both  groups.  In 
addition,  chi-square  test  was  used  to  examine  the 
differences  in  qualitative  variables  in  both  groups. 
Statistical significance was defined as p<0. 
 
Results  
Demographic Characteristics  
Demographic  characteristics  of  the  participants  are 
presented in Table 1. In this randomized, double-blind, 
placebo-controlled  clinical  trial,  proportion  of  males 
and females was similar in both groups (p=0.559). 
 
Table 1. Demographic characteristics of participated obese people 
Characteristics 
Intervention 
group 
(mean ± SD) 
Placebo group 
(mean ± SD) 
P 
value 
Age (year)  31±8  33±8  0.502 
Sex [N (%)] 
Male  7(23.3%)  9 (30%) 
0.559 
Female  23(76.7%)  21 (70%) 
 
Anthropometric Measurements 
Paired T-test analysis showed that there is a significant 
reduction  in  anthropometric  parameters  in  the 
intervention  group  (p<0.05).  The  changes  in  
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anthropometric  parameters  in  the  placebo  group, 
however,  were  not  significant  (p>0.05).  Regarding 
waist  circumference,  a  significant  reduction  was  also 
observed  in  the  intervention  group,  but  not  in  the 
placebo group (p<0.05).  
Results  obtained  from  the  ANCOVA  test  (Table  2) 
indicate that there is significant differences in weight 
and  BMI  indexes  between  the  intervention  and  the 
placebo  groups  after  adjusting  for  baseline 
measurements  (p<0.05).  Nevertheless,  reduction  of 
waist  circumference  was  not  significant  in  the 
intervention  group  after  adjusting  for  baseline  values 
(p>0.05). 
 
Table 2. Results of anthropometric measurements of zinc-supplemented obese people before and after intervention and between both groups. 
Components 
Intervention group 
p
a 
Placebo group 
p
a  p
b 
before  after  before  after 
Weight (Kg)  90.4±15.4  88.7±15  0.014*  91.13±20.1  91.11 ±20  0.851  0.020* 
Waist circumference (cm)  101.9±11.7  99.7±11.2  0.002*  100.2 ±11.8  99±11.2  0.058  0.319 
BMI (kg/m
2)  35.4±4.3  34.7±3.9  0.015*  33.5±5.9  33.4±6.1  0.860  0.030* 
*statistically significant, a: Paired t-test, b: ANCOVA test (between two groups with adjusting for baseline values) 
 
Biochemical Markers 
The participants’ biochemical markers obtained at the 
onset  of  the  study  and  at  the  end  of  it  were  further 
analyzed to compare the within-groups changes and the 
between-groups  changes.  The  within-groups  compa-
rison  of  biochemical  markers  revealed  no  significant 
changes in serum FBS, TC, LDL-C and HDL-C levels 
after intervention (p>0.05), however, TG concentration 
represented  significant  reduction  in  the  intervention 
group  (p<0.05).  Serum  zinc  concentration  increased 
significantly  in  the  intervention  group  at  the  end  of 
study (p<0.05). 
The  between-groups  comparison  of  biochemical 
markers at the end of the study indicated no significant 
change between groups in serum FBS, TC, LDL-C, TG 
and HDL-C levels. The increased level of serum zinc 
between  groups  was  significant  (p<0.05).  Table  3 
shows the results of biochemical markers. 
 
Table 3. Results of biochemical markers of zinc-supplemented obese subjects before and after intervention and between two groups 
Components 
Intervention group (mean± SD) 
p
a 
Placebo group (mean± SD) 
p
a  p
b 
before  after  before  after 
Fasting blood sugar (mg/dl)  96±9  94.9±13  0.535  86±3  90±4  0.210  0.103 
Triglyceride (mg/dl)  146.4±6  131.4±5  0.006*  147±7  144±5  0.677  0.127 
Total cholesterol (mg/dl)  185±30  182±34  0.472  153±39  156±35  0.648  0.489 
Low density lipoprotein (mg/dl)  104±22  103±25  0.694  86±25  85±22  0.888  0.340 
High density lipoprotein (mg/dl)  44±9  46±10  0.109  39±9  41±7  0.351  0.437 
Serum zinc (µg/dl)  67±19  74.1±23  0.024*  40.8±19  45.8±17  0.054  0<001* 
*statistically significant a: Paired t-test, b: ANCOVA test: between two groups with adjusting for baseline values 
 
Discussion 
Obesity  is  an  important  risk  factor  for  metabolic 
abnormality and many chronic diseases.
4 In this study, 
the  use  of  30  mg/d  zinc  was  higher  than  the 
recommended  dose  (DRIs  8-11  mg/day),  and  lower 
than the tolerable limit of highest intake (40 mg/day).
27 
There were no significant changes in serum FBS, HDL-
C, TC and LDL-C concentration at the end of the study 
but  significant  decrease  was  observed  in  serum  TG. 
According  to  a  Meta-analysis  investigation  results, 
regarding  the  effect  of  zinc  supplementation  on  lipid 
profiles were inconsistent.
28 Afkhami-Ardekani et al.,
29 
demonstrated  that  supplementation  of  forty  diabetic 
patients with 660 mg zinc sulfate for six weeks resulted 
in  a  remarkable  reduction  in  TG,  TC  and  LDL-C 
concentrations,  a  non-significant  increase  in  serum 
HDL-C concentration and non-significant reduction in 
FBS at the end of the study. Samman et al.,
30 found that 
serum  LDL-C,  TC  and  TG  concentration  were 
unaffected by supplementation with up to 150 mg zinc 
per  day.  Hooper  et  al.,
31  assessed  the  effects  of  440 
mg/day  zinc  supplementation  for  five  weeks  and 
reported no significant changes in TC, TG and LDL-C 
concentration  at  the  end  of  the  study.  However,  TG 
concentration decreased in this study.  
The  present  research  findings  were  in  line  with  of 
Roussel  et  al.,
32 and  Fortes  et  al.
33 studies.  Fortes  et 
al.,
33 reported that 25 mg zinc sulphate for three months 
resulted  in  a  decrease  in  plasma  lipid  peroxides. 
Mechanisms involved in improving lipid profiles  and 
glucose concentration are not clearly identified yet. It 
has been stated that zinc can play an important role in 
enzymes  involved  in  lipid  and  carbohydrate 
metabolism  and  similar  action  to  insulin.
34-36  It  has  
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been  suggested  that  higher  doses  of  zinc  and  longer 
periods  of  supplementation  can  be  effective  in 
remarkably  reduction  in  TG,  TC,  and  LDL-C 
concentration.
30 Low doses of zinc over short periods 
of intervention may be main reasons for non-significant 
changes  in  lipid  profiles  and  blood  glucose 
concentration.  
In  this  study,  serum  zinc  concentration  increased 
notably after intervention. Similar to our study's results, 
Christos et al.,
37 observed that supplementation with 30 
mg  elemental  zinc/day  (in  zinc  acetate  form)  for  12 
weeks and 60 mg elemental zinc/day (as zinc acetate) 
for 6 to 8 weeks resulted in an increase in plasma zinc 
concentration. Gomez et al.,
38 reported a significant rise 
in serum zinc concentration in 14 obese male subjects 
supplemented  with  100  mg/day  oral  zinc  sulfate 
(p=0.001). In contrast, in the study done by Marreiro 
and  coworkers
11  plasma  zinc  concentration  did  not 
increase significantly at the end of study.  
Regarding the anthropometric measurements, there was 
a significant reduction in weight, waist circumference 
and BMI indices  after intervention.  These results  are 
supported by Song et al. and Hashemipour et al. Song 
et al.,
21 demonstrated that supplementation of 30 obese 
male S-D rats divided in four groups of 5-6 rats with 
drinking (no additive, 10 mg zinc plus 1mg Cyclo-(His-
Pro) CHP. L-1, 10 mg zinc plus 3mg CHP.L-1 and 10 
mg zinc plus 6mg CHP.L-1) for 15 days resulted in a 
significant  reduction  in  weight  especially  in  rats  that 
were  receiving  10  mg  zinc  plus  3mg  CHP.L-1 
(p<0.01).  Likewise,  Hashemipour  et  al.,  found  that 
supplementation  with  20  mg  elemental  zinc  in  of  60 
obese children aged between 6-10 for 8 weeks resulted 
in  significant  reduction  of  BMI  and  weight  without 
changes in waist circumference.
39  
The effective mechanisms of zinc supplementation on 
weight loss can be due to 1) the role of zinc in appetite 
regulation  through  changes  in  hypothalamic 
neurotransmitter  metabolism  by  affecting  the  leptin 
system  and  its  receptors,  although  zinc  can  induce 
synthesis of leptin and prevention of hyperplasia
11 2) 
preventive role of zinc in the gene mutation which can 
increase  the  risk  of  obesity
40  3)  similarity  of  zinc  to 
insulin  action  and  improving  insulin  sensitivity  and 
insulin resistance.
36,41 
 
Conclusion 
The  results  of  this  study  indicated  that  one  month 
supplementation  of  zinc  gluconate  (30  mg/day)  in 
obese male and female adults resulted in a remarkable 
reduction  in  weight  and  BMI  indices  as  well  as  an 
increase in serum zinc concentration. However, serum 
lipid  profiles  and  fasting  blood  glucose  with  the 
exception of TG did not change noticeably. To the best 
of our knowledge, this was the first study in the region 
that investigated the effect of zinc supplementation on 
obese adults in both gender and it can be considered as 
the  strength  of  the  study.  Nevertheless,  there  was 
limitations such as short period of follow-up. It can be 
suggested that increasing the period of intervention and 
determining  the  safety  and  effectiveness  of  doses  of 
zinc supplementation be considered in future studies. 
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